project id: TCGA-PRAD; case submitter id: TCGA-EJ-7318; analyte type: DNA; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.84; age at index: 51; days to birth: -18686; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1960; age at diagnosis: 18686; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1029.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; days to collection: 757; initial weight: 650.0; oct embedded: true; sample id: aebabb43-b2aa-4fd0-87c0-08ae1d584f51; sample submitter id: TCGA-EJ-7318-01B; slide id: cabc240e-3adb-420d-89a2-1d98fbbe818e; slide submitter id: TCGA-EJ-7318-01B-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 40.0; percent tumor cells: 40.0; percent tumor nuclei: 60.0; section location: TOP;